PGAM2: A Potential Drug Target and Biomarker (G5224)

Target Name: PGAM2

NCBI ID: G5224

PGAM2

PGAM2: A Potential Drug Target and Biomarker

Phosphoglycerate mutase (PGAM2) is a enzyme involved in the metabolism of phosphoglycerate, a crucial molecule in cell signaling and energy production. The PGAM2 enzyme isozyme M has been identified as a potential drug target and biomarker for several diseases, including cancer, neurodegenerative diseases, and metabolic disorders.

In cancer, PGAM2 has been shown to play a critical role in cell signaling pathways, including the PI3K/Akt signaling pathway. This pathway is involved in the regulation of cell growth, survival, and angiogenesis, and is often disrupted in cancer cells. By inhibiting the activity of PGAM2, researchers have found that cancer cells are sensitive to various therapeutic approaches, including chemotherapy, radiation, and targeted therapies.

As a potential drug target, PGAM2 has been targeted by several small molecules and biochemicals. One of the most promising compounds is a drug called ALX148, which is a inhibitor of PGAM2. In preclinical studies, ALX148 has been shown to inhibit the growth of several cancer cell lines, including breast, ovarian, and colorectal cancer. The drug has also been shown to reduce the formation of new blood vessels in cancer cells, which can contribute to tumor growth.

Another compound that has been shown to interact with PGAM2 is called curcumin, a compound found in turmeric, a common spice. Curcumin has been shown to inhibit the activity of PGAM2 and has been shown to have anti-inflammatory and anti-cancer effects.

In neurodegenerative diseases, PGAM2 has been implicated in the development and progression of several disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. By targeting PGAM2, researchers have found that they can improve cognitive function, reduce neurodegeneration, and slow the progression of these disorders.

One of the most promising compounds for targeting PGAM2 in neurodegenerative diseases is a drug called Resveratrol, which is a natural compound found in red wine, grapes, and other plants. Resveratrol has been shown to inhibit the activity of PGAM2 and has been shown to improve cognitive function in animal models of Alzheimer's disease.

In metabolic disorders, PGAM2 has been shown to play a critical role in the regulation of cellular metabolism. It is involved in the metabolism of fatty acids, which are essential for brain function. PGAM2 has also been shown to play a critical role in the regulation of glucose metabolism, which is crucial for brain function.

One of the most promising compounds for targeting PGAM2 in metabolic disorders is a drug called Atogepant, which is a inhibitor of the enzyme ketolysis. Atogepant has been shown to improve insulin sensitivity and reduce inflammation in animal models of metabolic disorders.

In conclusion, PGAM2 is a versatile enzyme involved in a wide range of cellular processes that are important for human health. Its role in cell signaling pathways, including the PI3K/Akt signaling pathway, makes it an attractive target for drug development. The inhibition of PGAM2 by small molecules and biochemicals, such as ALX148, curcumin, and resveratrol, provides a promising avenue for the development of new treatments for cancer, neurodegenerative diseases, and metabolic disorders. Further research is needed to fully understand the role of PGAM2 in human health and to develop effective treatments.

Protein Name: Phosphoglycerate Mutase 2

Functions: Interconversion of 3- and 2-phosphoglycerate with 2,3-bisphosphoglycerate as the primer of the reaction. Can also catalyze the reaction of EC 5.4.2.4 (synthase), but with a reduced activity

The "PGAM2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PGAM2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets